Evidence map›Paper›PMID 37226407›Full record

Trial reportESC heart failure2023

The role of bioimpedance analysis in overweight and obese patients with acute heart failure: a pilot study.

Ana Venegas-Rodríguez, Ana María Pello, Marta López-Castillo, Mikel Taibo Urquía, Jorge Balaguer-Germán, Alicia Munté, Guillermo González-Martín, Sol María Carriazo-Julio, Juan Martínez-Milla, Andrea Kallmeyer and 5 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Bioimpedance utility in heart failure.Heart failure reviews · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Subclinical congestion assessed by whole-body bioelectrical impedance analysis in HFrEF outpatients.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2025
    Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Ana Venegas-RodríguezDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.ORCID 0000-0003-0603-0094
Ana María PelloDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Marta López-CastilloDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Mikel Taibo UrquíaDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Jorge Balaguer-GermánDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Alicia MuntéUniversidad Autónoma de Madrid, Ciudad Universitaria de Cantoblanco, Madrid, 28049, Spain.
Guillermo González-MartínDepartment of Nephrology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Sol María Carriazo-JulioDepartment of Nephrology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Juan Martínez-MillaDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Andrea KallmeyerDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Óscar González LorenzoDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Hans Paul Gaebelt SlockerDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
José TuñónDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Emilio González-ParraUniversidad Autónoma de Madrid, Ciudad Universitaria de Cantoblanco, Madrid, 28049, Spain.
Álvaro AceñaDepartment of Cardiology, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, Madrid, 28040, Spain.
Hospital Universitario Fundación Jiménez Díaz · ESSpanish National Centre for Cardiovascular Research · ESUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsResidual congestion at the time of hospital discharge is an important readmission risk factor, and its detection with physical examination and usual diagnostic techniques have strong limitations in overweight and obese patients. New tools like bioelectrical impedance analysis (BIA) could help to determine when euvolaemia is reached. The aim of this study was to investigate the usefulness of BIA in management of heart failure (HF) in overweight and obese patients. METHODS AND

resultsOur study is a single-centre, single-blind, randomized controlled trial that included 48 overweight and obese patients admitted for acute HF. The study population was randomized into two arms: BIA-guided group and standard care. Serum electrolytes, kidney function, and natriuretic peptides were followed up during their hospital stay and at 90 days after discharge. The primary endpoint was development of severe acute kidney injury (AKI) defined as an increase in serum creatinine by >0.5 mg/dL during hospitalization, and the main secondary endpoint was the reduction of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels during hospitalization and within 90 days after discharge. The BIA-guided group showed a remarkable lower incidence of severe AKI, although no significant differences were found (41.4% vs. 16.7%; P = 0.057). The proportion of patients who achieved levels of NT-proBNP < 1000 pg/mL at 90 days was significantly higher in the BIA-guided group than in the standard group (58.8% vs. 25%; P = 0.049). No differences were observed in the incidence of adverse outcomes at 90 days.

conclusionsAmong overweight and obese patients with HF, BIA reduces NT-proBNP levels at 90 days compared with standard care. In addition, there is a trend towards lower incidence of AKI in the BIA-guided group. Although more studies are required, BIA could be a useful tool in decompensated HF management in overweight and obese patients.

Indexed as

Heart FailureOverweightBiomarkersHumansNatriuretic Peptide, BrainObesityPilot ProjectsSingle-Blind MethodBiomarkersNatriuretic Peptide, BrainAcute kidney injuryBioimpedance analysisHeart failureNatriuretic peptidesObesity

Identifiers

PMID37226407
PMCPMC10375164
OpenAlexW4378173051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.